In the following video, Motley Fool health-care analyst David Williamson takes investors through one possible boom for Eli Lilly (LLY +0.12%), and one major potential bust. The company does have several major catalysts coming in the near term for drugs in its pipeline aimed both at stomach cancer and diabetes, but will these be enough to counteract losses from a major patent cliff coming up for the company? David gives his opinion on Eli's pipeline, and just how bad the patent cliff could be.
Eli Lilly's Boom-or-Bust Potential
By Dave Williamson – Mar 26, 2013 at 7:30PM
NYSE: LLY
Eli Lilly
Market Cap
$782B
Today's Change
(0.12%) $0.96
Current Price
$826.41
Price as of October 27, 2025 at 4:00 PM ET
Can Eli Lilly's pipeline arsenal beat back losses from a very steep patent cliff on the horizon?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid